Prevalence of dyslipidemia and goal attainment after initiating lipid-modifying therapy: a Thai multicenter study.
Previous studies focused on attaining low-density lipoprotein cholesterol (LDL-C) goals after lipid-modifying therapy (LMT), but data on achieving normal levels of triglyceride and high-density lipoprotein cholesterol (HDL-C) are limited. We reviewed medical records of patients initiated on LMT. High risk was defined as patients with coronary heart disease, diabetes, or 10-year Framingham risk >20%. Among 806 patients enrolled, 429 were at high risk. Prior to initiation of LMT, 66%, 35%, and 44% overall and 69%, 35%, and 45% in the high-risk group had elevated LDL-C, elevated triglyceride, and low HDL-C, respectively. After 12 months of LMT, 21%, 32%, and 39% overall and 26%, 25%, and 43% in the high-risk group still had elevated LDL-C, elevated triglyceride, and low HDL-C, respectively. Approximately 1 of 5 patients continued to experience elevated LDL-C coupled with elevated triglyceride and/or low HDL-C. In conclusion, a substantial proportion of patients initiated on LMT continued to have lipid abnormalities.
Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand. wkhovid@gmail.com
Weerapan
W
Khovidhunkit
Songkwan
S
Silaruks
Vithaya
V
Chaithiraphan
Boonsong
B
Ongphiphadhanakul
Piyamitr
P
Sritara
Hataikarn
H
Nimitphong
Thanawat
T
Benjanuwattra
Baishali M
BM
Ambegaonkar
D000328:Adult; D000818:Animals; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology; D003430:Cross-Sectional Studies; D003906:Developing Countries; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy; D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology*; D005260:Female; D058607:Fibric Acids / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006784:Hospitals, Teaching; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010353:Patient Education as Topic; D012189:Retrospective Studies; D013785:Thailand; D014280:Triglycerides / Q000097:blood
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D058607:Fibric Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D014280:Triglycerides